Synthesis
Compound III [3] was synthesized according to the published procedure.
7-(Dimethylamino)-N-(2-(dimethylamino)ethyl)-2-oxo-2H-chromene-3-carboxamide
(2A). Ethyl 7-(dimethylamino)-2-oxo-2H-chromene-3-carboxylate (300 mg, 1.15 mmol, 1.0 equiv) and N 1 ,N 1 -dimethylethane-1,2-diamine (286 µL, 2.3 mmol, 2.0 equiv) were suspended in dry ethanol (30 mL) and refluxed for 15 h. Solvent was removed under reduced pressure and the residue was dissolved in DCM (50 mL). The solution was washed with water (5×50 mL), brine (50 mL) and dried over anhydrous Na2SO4. The solvent was evaporated and the product was purified by flash column chromatography using DCM/MeOH (from 20:1 to 10/1, v/v) as the eluent to produce 225 mg of compound 2B as a yellow solid (64% yield). 1 H NMR (400 MHz, MeOD) δ 7.54 (d, J = 9.0 Hz, 1H), 6.81 (dd, J = 9.0, 2.4 Hz, 1H), 6.55 (d, J = 2.3 Hz, 1H), 3.56 (t, J = 6.6 Hz, 2H), 2.61 (t, J = 6.6 Hz, 2H 
2-(7-(Dimethylamino)-2-oxo-2H-chromene-3-carboxamido)-N,N,N-trimethylethan-1aminium iodide (2B)
7-(Dimethylamino)-N-(2-(dimethylamino)ethyl)-2-oxo-2H-chromene-3-carboxamide (2A) (100 mg, 0.33 mmol, 1.0 equiv) was dissolved in DCM (10 mL) followed by addition of MeI (27 µL, 0.43 mmol,1.3 equiv). Product started to precipitate while reaction mixture was stirred at room temperature for 24 h. Product was filtered off and dried to give 95 mg of compound 2C as a yellow solid (65% yield). 1 H NMR (400 MHz, MeOD) δ 7.60 (d, J = 9.0 Hz, 1H), 6.87 (dd, J = 9.0, 2.5 Hz, 1H), 6 Compounds IV [4] and V [5] were synthesized according to the published procedures.
N-((1-((2-(7-(Diethylamino)-2-oxo-2H-chromen-3-yl)thiazol-4-yl)methyl)piperidin-3yl)methyl)-N-(2-(dimethylamino)ethyl)-2-naphthamide (2C)
. K2CO3 (47 mg, 0.34 mmol, 2.0 equiv), 3-(4-(chloromethyl)thiazol-2-yl)-7-(diethylamino)-2H-chromen-2-one (IV) (62 mg, 0.18 mmol, 1 equiv), and N-(2-(dimethylamino)ethyl)-N-(piperidin-3-ylmethyl)-2naphthamide (V) (60 mg, 0.18 mmol, 1 equiv) were suspended in acetonitrile (5 mL) and the reaction mixture was stirred at 60 °C for 48 h. The solvent was removed under reduced pressure and the crude product was purified by flash column chromatography using DCM/MeOH/NH4(aq) (100:5:1, v/v) as the eluent to produce 38 mg of probe 2C as an orange solid (32% yield). 
7-(Diethylamino)-N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-2-oxo-2H-chromene-3carboxamide (VII).
7-(Diethylamino)-2-oxo-2H-chromene-3-carboxylic acid (II) (515 mg, 1.97 mmol, 1.0 equiv) was suspended in CH2Cl2 (25 mL) and cooled to 0 °C. The solution was stirred and dimethylformamide (50 µL) was added, followed by dropwise addition of oxalyl chloride (334 µL, 3.94 mmol, 2.0 equiv). The reaction mixture was stirred at 0 °C for 5 minutes, then at reflux conditions for 30 minutes. Solvent was removed under reduced pressure and the residue was dissolved in CH2Cl2 (10 mL) and cooled to 0 °C. This solution was added dropwise to the solution of 2-(2-(2-aminoethoxy)ethoxy)ethan-1-ol (VI) (440 mg, 2.95 mmol, 1.5 equiv) and Et3N (327 µL, 2.24 mmol, 1.2 eqiuv) in CH2Cl2 (25 mL) cooled to 0 °C. The reaction mixture was allowed to reach room temperature and stirred for 2 h. The mixture was transferred to separating funnel, washed with 1 M HCl (25 mL), brine (15 mL) and dried over anhydrous Na2SO4. Solvent was evaporated to produce the crude product, which was purified by flash column chromatography using DCM/MeOH (from 50:1 to 10:1, v/v) as the eluent to produce 422 mg of compound VII as a yellow oil (54% yield). 
N-(2-(2-(2-Bromoethoxy)ethoxy)ethyl)-7-(diethylamino)-2-oxo-2H-chromene-3carboxamide (VIII).
7-(Diethylamino)-N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-2-oxo-2H-chromene-3carboxamide (IX) (403 mg, 1.03 mmol, 1 eqiuv) was dissolved CH2Cl2 (15 mL) and cooled to 0 °C. The solution was stirred and Et3N (185 µL, 134 mmol, 1.3 equiv) was added, followed by dropwise addition of mesyl chloride (88 µL, 1.13 mmol, 1.1 eqiuv). The reaction mixture was allowed to reach room temperature and stirred for 1 h. The mixture was transferred to separating funnel, washed with 1 M HCl (25 mL), brine (20 mL) and dried over anhydrous Na2SO4. Solvent was evaporated and the residue was dissolved in acetone (20 mL). LiBr (1.77 g, 20.6 mmol, 20 equiv) was added portionwise to the stirred solution. The reaction mixture was heated to 60 °C and stirred for 15 h. Solvent was evaporated, and the residues suspended in EtOAc (30 mL). The mixture was transferred to separating funnel, washed with water (30 mL), brine (20 mL) and dried over anhydrous Na2SO4. Solvent was evaporated to produce the crude product, which was purified by flash column chromatography using EtOAc/Hex (from 1:2 to 3:1, v/v) as the eluent to produce 194 mg of compound VIII as a yellow oil (41% yield). N-(2-(2-(2-(N-((1-Benzylpiperidin-3-yl) Compound X [7] was synthesized according to the published procedure.
4-(4-(2-Bromoethyl)piperazin-1-yl)-7-nitrobenzo[c][1,2,5]oxadiazole (XI).
2-(4-(7-Nitrobenzo[c][1,2,5]oxadiazol-4-yl)piperazin-1-yl)ethan-1-ol (X) (560 mg, 1.91 mmol, 1.0 equiv) was dissolved CH2Cl2 (5 mL) and cooled to 0 °C. The solution was stirred and Et3N (528 µL, 3.82 mmol, 2.0 equiv) was added, followed by dropwise addition of mesyl chloride (155 µL, 2.0 mmol, 1.05 equiv). The reaction mixture was allowed to reach room temperature and stirred for 30 min. DCM (25 mL) was added to the reaction mixture, and the solution was transferred to separating funnel, washed with water (20 mL), saturated aqueous NaHCO3 solution (20 mL), brine (15 mL) and dried over anhydrous Na2SO4. Solvent was evaporated and the residue was dissolved in acetone (10 mL). The solution was stirred, and LiBr (1.66 g, 19.1 mmol, 10 equiv) was added. The reaction mixture was heated to 50 °C and stirred for 1 h. Solvent was evaporated and the residue was suspended in EtOAc (20 mL). The mixture was transferred to separating funnel, washed with water (20 mL), brine (20 mL) and dried over anhydrous Na2SO4. Solvent was evaporated to produce 467 mg of crude product (69%), which was used immediately in the next reaction step without further purification. ((1-Benzylpiperidin-3-yl)methyl)-N-(2-(4-(7-nitrobenzo[c][1,2,5]oxadiazol-4yl) piperazin-1-yl)ethyl)naphthalene-2-sulfonamide (3B). N-(2-(2-Azidoethoxy)ethyl)-N-((1-benzylpiperidin-3-yl) methyl)naphthalene-2sulfonamide (3C). Benzylpiperidin-3-yl) methyl)naphthalene-2-sulfonamide (IX) (100 mg, 0.25 mmol, 1.0 equiv), 1-azido-2-(2-bromoethoxy)ethane (XII) (74 mg, 0.38 mg, 1.5 equiv) and Cs2CO3 (165.5 mg, 0.51 mmol, 2.0 equiv) were suspended in ACN (5 mL), and stirred at 60 °C for 3 days. Solvents were removed under reduced pressure and the crude product was purified by flash column chromatography using DCM/MeOH (from 9:1 to 9:2, v/v) as the eluent to produce 71 mg of azide 3C as a yellow viscous oil (56% yield). N-((1-Benzylpiperidin-3-yl)methyl)-N-(2-(2-(4-((4-(7-nitrobenzo[c][1,2,5] Figure S1 . BChE activity histochemical staining of coronal cryosections (10 μm) of a rat brain from two regions at the level of the thalamus. All sections were processed with 0.1 mM BW-284C51 in Koelle solution to completely block the AChE activity (A, B). For the inhibition experiment, the sections were incubated with compounds 2C (1 mM, C, D) and 3B (1 mM, E, F), respectively. The relative optical density (ROD) pseudocolor scale for the staining intensity of BChE activity is shown on the right. The photomicrographs show BChE-rich neurons in the laterodorsal thalamic nucleus (arrows) and the capillaries in the cerebral cortex in the absence (a, b) and the presence of compounds 2C (c, d) and 3B (e, f). Magnification of the photomicrographs is 20×. Figure S2 . The fluorescence titration data, in duplicate, were simultaneously fitted to the sum of hyperbolic and linear equation. The determined binding constant for probe 2C was 5.5 +/-1.6 nM, remarkably similar to the inhibition constant for the binding to the free enzyme (3.3 nM, see Table 1 in the main text).
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